INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF

1 . A compound of Formula (1):

or a pharmaceutically acceptable salt thereof wherein

A is the following Formula (A-1), Formula (A-2), Formula (A-3), or Formula (A-4):

wherein

l is an integer of 0 to 4,

m is an integer of 0 to 2,

n is an integer of 0 to 2,

o and p are independently an integer of 0 or 1,

q is an integer of 0 to 5,

(A-1) to (A-4) may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of C 1-6 alkyl group, C 2-6 alkenyl group, C 2-6 alkynyl group, hydroxy group, C 1-6 alkoxy group, and halogen atom at each substitutable position thereof,

B is the following Formula (B-1), Formula (B-2), or Formula (B-3):

wherein (B-2) and (B-3) may optionally include an unsaturated bond(s) at an acceptable position(s) of the ring, provided that D is absent when B is (B-1),

R 8 , R 9 and D are independently a group selected from the group consisting of the following (1) and (2):

(1) hydrogen atom, an optionally-substituted C 1-6 alkyl group, an optionally-substituted C 3-6 alkenyl group, an optionally-substituted C 3-6 alkynyl group, an optionally-substituted C 3-8 monocyclic, C 7-10 bicyclic or C 7-12 tricyclic cycloalkyl group, and an optionally-substituted C 5-8 monocyclic or C 7-10 bicyclic cycloalkenyl group

wherein the C 1-6 alkyl group, C 3-6 alkenyl group, C 3-6 alkynyl group, C 3-8 monocyclic, C 7-10 bicyclic or C 7-12 tricyclic cycloalkyl group, and C 5-8 monocyclic or C 7-10 bicyclic cycloalkenyl group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of C 1-4 alkyl group, hydroxy group, C 1-4 alkoxy group, C 1-4 haloalkyl group, C 1-4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, aryloxy group, C 2-6 alkanoyl group, phenacyl group, and halogen atom at each substitutable position thereof;

(2) —(CH 2 ) u —R 12

wherein u is an integer of 0 to 4 provided that when u is an integer of 1 to 4, the alkylene chain may be optionally substituted with one or more substituents independently-selected from the group consisting of C 1-6 alkyl group, C 2-6 alkenyl group, C 2-6 alkynyl group, hydroxy group, C 1-6 alkoxy group, oxo group, and halogen atom,

R 12 is the following Formula (R 12 -1), Formula (R 12 -2), Formula (R 12 -3), Formula (R 12 -4), Formula (R 12 -5), Formula (R 12 -6), Formula (R 12 -7), or Formula (R 12 -8):

wherein R 13 is a group selected from the group consisting of the following (1) to (5):

(1) hydrogen atom and formyl group;

(2) an optionally-substituted C 1-6 alkyl group, an optionally-substituted C 3-6 alkenyl group, an optionally-substituted C 3-6 alkynyl group, an optionally-substituted C 3-8 cycloalkyl group, and an optionally-substituted C 5-8 cycloalkenyl group

wherein the C 1-6 alkyl group, C 3-6 alkenyl group, C 3-6 alkynyl group, C 3-8 cycloalkyl group, and C 5-8 cycloalkenyl group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of C 1-4 alkyl group, hydroxy group, C 1-4 alkoxy group, C 1-4 haloalkyl group, C 1-4 haloalkoxy group, cyano group, oxo group, and halogen atom at each substitutable position thereof;

(3) —COR 16 , —CSR 16 , —SO 2 R 16 , —CO—COR 16 , —COOR 16 , and —CO—COOR 16

wherein R 16 is an optionally-substituted C 1-6 alkyl group, an optionally-substituted C 3-6 alkenyl group, an optionally-substituted C 3-6 alkynyl group, an optionally-substituted C 3-8 cycloalkyl group, an optionally-substituted C 5-8 cycloalkenyl group, an optionally-substituted aryl group, an optionally-substituted heteroaryl group, an optionally-substituted 5- to 9-membered monocyclic or 7- to 10-membered bicyclic non-aromatic unsaturated heterocyclic group (wherein the binding site is any one carbon atom in the heterocyclic ring), or an optionally-substituted 4- to 9-membered monocyclic or 7- to 10-membered bicyclic saturated heterocyclic group (wherein the binding site is any one carbon atom in the heterocyclic ring),

wherein the C 1-6 alkyl group, C 3-6 alkenyl group, C 3-6 alkynyl group, C 3-8 cycloalkyl group, C 5-8 cycloalkenyl group, 5- to 9-membered monocyclic or 7- to 10-membered bicyclic non-aromatic unsaturated heterocyclic group, and 4- to 9-membered monocyclic or 7- to 10-membered bicyclic saturated heterocyclic group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of C 1-4 alkyl group, hydroxy group, C 1-4 alkoxy group, C 1-4 haloalkyl group, C 1-4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, and halogen atom at each substitutable position thereof; and the aryl group and heteroaryl group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of halogen atom, hydroxy group, C 1-4 alkyl group, C 1-4 alkoxy group, C 1-4 haloalkyl group, C 1-4 haloalkoxy group, cyano group, nitro group, C 2-6 alkanoyl group, and an optionally-substituted amino group at each substitutable position thereof;

(4) —CONR 17 —OR 18

wherein R 17 and R 18 are independently hydrogen atom, C 1-6 alkyl group, C 3-6 alkenyl group or C 3-6 alkynyl group;

(5) —CONR 19 R 20 , —CSNR 19 R 20 and —SO 2 NR 19 R 20

wherein R 19 and R 20 are independently hydrogen atom or any group defined in the said R 16 , or

R 19 and R 20 may be taken together with the adjacent nitrogen atom to form a saturated or unsaturated 4- to 8-membered monocyclic nitrogen-containing heterocyclic group comprising additional 0 to 2 heteroatoms independently-selected from the group consisting of 1 to 2 nitrogen atoms, 1 oxygen atom and 1 sulfur atom wherein the heterocyclic group may be optionally substituted with one or more substituents independently-selected from the group consisting of C 1-4 alkyl group, hydroxy group, C 1-4 alkoxy group, C 1-4 haloalkyl group, C 1-4 haloalkoxy group, cyano group, oxo group, and halogen atom at each substitutable position thereof,

R 14 and R 15 are independently hydrogen atom, an optionally-substituted C 1-6 alkyl group, an optionally-substituted C 3-6 alkenyl group, an optionally-substituted C 3-6 alkynyl group, an optionally-substituted C 3-8 cycloalkyl group, an optionally-substituted C 5-8 cycloalkenyl group, an optionally-substituted aryl group, an optionally-substituted heteroaryl group, an optionally-substituted 5- to 9-membered monocyclic or 7- to 10-membered bicyclic non-aromatic unsaturated heterocyclic group (which is attached to the adjacent nitrogen atom via any one carbon atom in the heterocyclic group), an optionally-substituted 4- to 9-membered monocyclic or 7- to 10-membered bicyclic saturated heterocyclic group (which is attached to the adjacent nitrogen atom via any one carbon atom in the heterocyclic group), C 2-6 alkanoyl group, C 1-6 alkoxycarbonyl group, carbamoyl group, sulfamoyl group, or C 1-6 alkylsulfonyl group,

wherein the C 1-6 alkyl group, C 3-6 alkenyl group, C 3-6 alkynyl group, C 3-8 cycloalkyl group, C 5-8 cycloalkenyl group, 5- to 9-membered monocyclic or 7- to 10-membered bicyclic non-aromatic unsaturated heterocyclic group, 4- to 9-membered monocyclic or 7- to 10-membered bicyclic saturated heterocyclic group, C 2-6 alkanoyl group, C 1-6 alkoxycarbonyl group, and C 1-6 alkylsulfonyl group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of C 1-4 alkyl group, hydroxy group, C 1-4 alkoxy group, cyano group, oxo group, aryl group, heteroaryl group, and halogen atom at each substitutable position thereof; and the aryl group and heteroaryl group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of halogen atom, hydroxy group, C 1-4 alkyl group, C 1-4 alkoxy group, cyano group, nitro group, C 2-6 alkanoyl group, and an optionally-substituted amino group at each substitutable position thereof, or

R 14 and R 15 may be taken together with the adjacent nitrogen atom to form a saturated or unsaturated 4- to 9-membered monocyclic or 7- to 10-membered bicyclic nitrogen-containing heterocyclic group comprising additional 0 to 2 heteroatoms independently-selected from the group consisting of 1 to 2 nitrogen atoms, 1 oxygen atom and 1 sulfur atom wherein the heterocyclic group may be optionally substituted with one or more substituents independently-selected from the group consisting of C 1-4 alkyl group, hydroxy group, C 1-4 alkoxy group, C 1-4 haloalkyl group, C 1-4 haloalkoxy group, cyano group, oxo group, and halogen atom at each substitutable position thereof,

(R 12 -1) to (R 12 -4) may optionally include an unsaturated bond(s) at an acceptable position(s) of the ring,

R 8 ′ and R 9 ′ are independently hydrogen atom, an optionally-substituted C 1-6 alkyl group, an optionally-substituted C 3-6 alkenyl group, an optionally-substituted C 3-6 alkynyl group, an optionally-substituted C 3-8 cycloalkyl group, an optionally-substituted C 5-8 cycloalkenyl group, an optionally-substituted aryl group, an optionally-substituted heteroaryl group, an optionally-substituted 5- to 9-membered monocyclic or 7- to 10-membered bicyclic non-aromatic unsaturated heterocyclic group (which is attached to the adjacent nitrogen atom via any one carbon atom in the heterocyclic group), or an optionally-substituted 4- to 9-membered monocyclic or 7- to 10-membered bicyclic saturated heterocyclic group (which is attached to the adjacent nitrogen atom via any one carbon atom in the heterocyclic group),

wherein the C 1-6 alkyl group, C 3-6 alkenyl group, C 3-6 alkynyl group, C 3-8 cycloalkyl group, C 5-8 cycloalkenyl group, 5- to 9-membered monocyclic or 7- to 10-membered bicyclic non-aromatic unsaturated heterocyclic group, and 4- to 9-membered monocyclic or 7- to 10-membered bicyclic saturated heterocyclic group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of C 1-4 alkyl group, hydroxy group, C 1-4 alkoxy group, C 1-4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, aryloxy group, C 2-6 alkanoyl group, phenacyl group, and halogen atom at each substitutable position thereof; and the aryl group and heteroaryl group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of halogen atom, hydroxy group, C 1-4 alkyl group, C 1-4 alkoxy group, C 1-4 haloalkyl group, C 1-4 haloalkoxy group, cyano group, nitro group, C 2-6 alkanoyl group, and an optionally-substituted amino group at each substitutable position thereof, or a pair of R 8 and R 9 , and a pair of R 8 and R 9 ′ may be independently taken together with the adjacent nitrogen atom to form a saturated or unsaturated 4- to 9-membered monocyclic or 7- to 10-membered bicyclic nitrogen-containing heterocyclic group comprising additional 0 to 2 heteroatoms independently-selected from the group consisting of 1 to 2 nitrogen atoms, 1 oxygen atom and 1 sulfur atom wherein the nitrogen-containing heterocyclic group may be optionally substituted with one or more substituents independently-selected from the group consisting of C 1-4 alkyl group, hydroxy group, C 1-4 alkoxy group, C 1-4 haloalkyl group, C 1-4 haloalkoxy group, cyano group, oxo group, and halogen atom at each substitutable position thereof,

R 10 , R 10 ′, R 11 and R 11 ′ are independently hydrogen atom, halogen atom, hydroxy group, an optionally-substituted C 1-6 alkyl group, an optionally-substituted C 2-6 alkenyl group, an optionally-substituted C 2-6 alkynyl group, an optionally-substituted C 1-6 alkoxy group, cyano group, or an oxo group,

wherein the C 1-6 alkyl group, C 2-6 alkenyl group, C 2-6 alkynyl group, and C 1-6 alkoxy group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of C 1-4 alkyl group, hydroxy group, C 1-4 alkoxy group, C 1-4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, aryloxy group, C 2-6 alkanoyl group, phenacyl group, and halogen atom at each substitutable position thereof, or

a pair of R 10 and R 11 , and a pair of R 10 ′ and R 11 ′ may be independently taken together to form an optionally-substituted saturated or unsaturated 3- to 8-membered ring that may comprise 1 oxygen atom, which may be a bicyclic or a spiro compound with the ring to which the pair of R 10 and R 11 , or R 10 ′ and R 11 ′ is attached,

wherein the saturated or unsaturated 3- to 8-membered ring may be optionally substituted with one or more substituents independently-selected from the group consisting of C 1-4 alkyl group, hydroxy group, C 1-4 alkoxy group, C 1-4 haloalkyl group, C 1-4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, aryloxy group, C 2-6 alkanoyl group, phenacyl group, and halogen atom at each substitutable position thereof,

r and r′ are independently an integer of 0 to 3,

s and s′ are independently an integer of 0 to 3,

t and t′ are independently 1 or 2,

v is an integer of 0 to 2,

provided that not both r and s are 0,

V is nitrogen atom or C—R 1 wherein R 1 is hydrogen atom, halogen atom, an optionally-substituted C 1-6 alkyl group, an optionally-substituted C 2-6 alkenyl group, an optionally-substituted C 2-6 alkynyl group, an optionally-substituted C 3-8 cycloalkyl group, an optionally-substituted C 5-8 cycloalkenyl group, an optionally-substituted aryl group, or an optionally-substituted heteroaryl group,

wherein the C 1-6 alkyl group, C 2-6 alkenyl group, C 2-6 alkynyl group, C 3-8 cycloalkyl group, and C 5-8 cycloalkenyl group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of C 1-4 alkyl group, hydroxy group, C 1-4 alkoxy group, C 1-4 haloalkyl group, C 1-4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, aryloxy group, C 2-6 alkanoyl group, phenacyl group, and halogen atom at each substitutable position thereof; and the aryl group and heteroaryl group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of halogen atom, hydroxy group, C 1-4 alkyl group, C 1-4 alkoxy group, C 1-4 haloalkyl group, C 1-4 haloalkoxy group, cyano group, nitro group, C 2-6 alkanoyl group, and an optionally-substituted amino group at each substitutable position thereof,

W is nitrogen atom or C—R 2 wherein R 2 is hydrogen atom, halogen atom, hydroxy group, an optionally-substituted C 1-6 alkyl group, an optionally-substituted C 2-6 alkenyl group, an optionally-substituted C 2-6 alkynyl group, an optionally-substituted C 3-8 cycloalkyl group, an optionally-substituted C 5-8 cycloalkenyl group, an optionally-substituted C 1-6 alkoxy group, an optionally-substituted C 1-4 haloalkyl group, an optionally-substituted C 1-4 haloalkoxy group, cyano group, nitro group, an optionally-substituted aryl group, an optionally-substituted heteroaryl group, or an optionally-substituted amino group,

wherein the C 1-6 alkyl group, C 2-6 alkenyl group, C 2-6 alkynyl group, C 3-8 cycloalkyl group, C 5-8 cycloalkenyl group, C 1-6 alkoxy group, C 1-4 haloalkyl group, and C 1-4 haloalkoxy group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of C 1-4 alkyl group, hydroxy group, C 1-4 alkoxy group, C 1-4 haloalkyl group, C 1-4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, aryloxy group, C 2-6 alkanoyl group, phenacyl group, and halogen atom at each substitutable position thereof; and the aryl group and heteroaryl group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of halogen atom, hydroxy group, C 1-4 alkyl group, C 1-4 alkoxy group, C 1-4 haloalkyl group, C 1-4 haloalkoxy group, cyano group, nitro group, C 2-6 alkanoyl group, and an optionally-substituted amino group at each substitutable position thereof,

provided that when V is C—R 1 , W is nitrogen atom, and when V is nitrogen atom, W is C—R 2 ,

U is carbon atom or nitrogen atom,

X, Y and Z are independently selected from the group consisting of oxygen atom, nitrogen atom, sulfur atom and carbon atom, provided that at least one of X, Y and Z is oxygen atom, sulfur atom, or nitrogen atom,

provided that thiazole and oxazole rings are excluded from the 5-membered heteroaryl ring comprising X, Y and Z,

R 3 is hydrogen atom, halogen atom, an optionally-substituted C 1-6 alkyl group, an optionally-substituted C 2-6 alkenyl group, an optionally-substituted C 2-6 alkynyl group, an optionally-substituted C 3-8 cycloalkyl group, an optionally-substituted C 5-8 cycloalkenyl group, an optionally-substituted C 1-6 alkoxy group, an optionally-substituted C 1-4 haloalkyl group, an optionally-substituted C 1-4 haloalkoxy group, cyano group, nitro group, an optionally-substituted aryl group, an optionally-substituted heteroaryl group, an optionally-substituted 5- to 9-membered monocyclic or 7- to 10-membered bicyclic non-aromatic unsaturated heterocyclic group, or an optionally-substituted 4- to 9-membered monocyclic or 7- to 10-membered bicyclic saturated heterocyclic group,

wherein the C 1-6 alkyl group, C 2-6 alkenyl group, C 2-6 alkynyl group, C 3-8 cycloalkyl group, C 5-8 cycloalkenyl group, C 1-6 alkoxy group, C 1-4 haloalkyl group, C 1-4 haloalkoxy group, 5- to 9-membered monocyclic or 7- to 10-membered bicyclic non-aromatic unsaturated heterocyclic group, and 4- to 9-membered monocyclic or 7- to 10-membered bicyclic saturated heterocyclic group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of C 1-4 alkyl group, hydroxy group, C 1-4 alkoxy group, C 1-4 haloalkyl group, C 1-4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, aryloxy group, C 2-6 alkanoyl group, phenacyl group, and halogen atom at each substitutable position thereof; and the aryl group and heteroaryl group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of halogen atom, hydroxy group, C 1-4 alkyl group, C 1-4 alkoxy group, C 1-4 haloalkyl group, C 1-4 haloalkoxy group, cyano group, nitro group, C 2-6 alkanoyl group, and an optionally-substituted amino group at each substitutable position thereof,

R 4 is hydrogen atom, halogen atom, hydroxy group, an optionally-substituted C 1-6 alkyl group, an optionally-substituted C 2-6 alkenyl group, an optionally-substituted C 2-6 alkynyl group, an optionally-substituted C 3-8 cycloalkyl group, an optionally-substituted C 5-8 cycloalkenyl group, an optionally-substituted C 1-6 alkoxy group, an optionally-substituted C 1-4 haloalkyl group, an optionally-substituted C 1-4 haloalkoxy group, cyano group, nitro group, an optionally-substituted aryl group, an optionally-substituted heteroaryl group, or an optionally-substituted amino group,

wherein the C 1-6 alkyl group, C 2-6 alkenyl group, C 2-6 alkynyl group, C 3-8 cycloalkyl group, C 5-8 cycloalkenyl group, C 1-6 alkoxy group, C 1-4 haloalkyl group, and C 1-4 haloalkoxy group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of C 1-4 alkyl group, hydroxy group, C 1-4 alkoxy group, C 1-4 haloalkyl group, C 1-4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, aryloxy group, C 2-6 alkanoyl group, phenacyl group, and halogen atom at each substitutable position thereof; and the aryl group and heteroaryl group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of halogen atom, hydroxy group, C 1-4 alkyl group, C 1-4 alkoxy group, C 1-4 haloalkyl group, C 1-4 haloalkoxy group, cyano group, nitro group, C 2-6 alkanoyl group, and an optionally-substituted amino group at each substitutable position thereof, or

R 3 and R 4 may be taken together to form a saturated or unsaturated 6- to 9-membered ring optionally comprising 1 oxygen atom wherein the ring may be optionally substituted with one or more substituents independently-selected from the group consisting of C 1-4 alkyl group, hydroxy group, C 1-4 alkoxy group, C 1-4 haloalkyl group, C 1-4 haloalkoxy group, cyano group, oxo group, and halogen atom at each substitutable position thereof, and

R 5 and R 6 are independently hydrogen atom, halogen atom, hydroxy group, an optionally-substituted C 1-6 alkyl group, an optionally-substituted C 2-6 alkenyl group, an optionally-substituted C 2-6 alkynyl group, an optionally-substituted C 3-8 cycloalkyl group, an optionally-substituted C 5-8 cycloalkenyl group, an optionally-substituted C 1-6 alkoxy group, an optionally-substituted C 1-4 haloalkyl group, an optionally-substituted C 1-4 haloalkoxy group, cyano group, nitro group, an optionally-substituted aryl group, an optionally-substituted heteroaryl group, or an optionally-substituted amino group,

wherein the C 1-6 alkyl group, C 2-6 alkenyl group, C 2-6 alkynyl group, C 3-8 cycloalkyl group, C 5-8 cycloalkenyl group, C 1-6 alkoxy group, C 1-4 haloalkyl group, and C 1-4 haloalkoxy group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of C 1-4 alkyl group, hydroxy group, C 1-4 alkoxy group, C 1-4 haloalkyl group, C 1-4 haloalkoxy group, cyano group, oxo group, aryl group, heteroaryl group, aryloxy group, C 2-6 alkanoyl group, phenacyl group, and halogen atom at each substitutable position thereof; and the aryl group and heteroaryl group may be independently and optionally substituted with one or more substituents independently-selected from the group consisting of halogen atom, hydroxy group, C 1-4 alkyl group, C 1-4 alkoxy group, C 1-4 haloalkyl group, C 1-4 haloalkoxy group, cyano group, nitro group, C 2-6 alkanoyl group, and an optionally-substituted amino group at each substitutable position thereof.

2 . The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein V is nitrogen atom and W is C—R 2 .

3 . The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R 3 is hydrogen atom, halogen atom, an optionally-substituted C 1-6 alkyl group, an optionally-substituted C 2-6 alkenyl group, an optionally-substituted C 2-6 alkynyl group, an optionally-substituted C 3-8 cycloalkyl group, or an optionally-substituted C 5-8 cycloalkenyl group.

4 . The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R 4 and R 5 are hydrogen atom, and R 2 and R 6 are independently hydrogen atom, halogen atom, an optionally-substituted C 1-6 alkyl group, an optionally-substituted C 1-6 alkoxy group, an optionally-substituted C 1-4 haloalkyl group, an optionally-substituted C 1-4 haloalkoxy group, or cyano group.

5 . The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein U is carbon atom.

6 . The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein X is nitrogen atom, Y is oxygen atom, and Z is nitrogen atom.

7 . The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein A is (A-1), and 1 is an integer of 0 or 1.

8 . The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein B is (B-2), s is an integer of 1, and r is an integer of 1 or 2.

9 . The compound of claim 1 which has a chemical structure of Formula (12):

or a pharmaceutically acceptable salt thereof.

10 . The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein D is hydrogen atom, an optionally-substituted C 1-6 alkyl group, or an optionally-substituted C 3-8 monocyclic, C 7-10 bicyclic or C 7-12 tricyclic cycloalkyl group.

11 . The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein D is —(CH 2 ) u —R 12 , and R 12 is Formula (R 12 -3).

12 . The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein D is —(CH 2 ) u —R 12 , and R 12 is Formula (R 12 -1).

13 . The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein A is (A-3), o is an integer of 0, p is an integer of 0, q is an integer of either 1 or 3, and B is (B-1).

14 . The compound of claim 1 which has a chemical structure of Formula (13):

or a pharmaceutically acceptable salt thereof.

15 . The compound of claim 1 which is selected from the group consisting of the following compounds or a pharmaceutically acceptable salt thereof:

(01) 1-{5-[1-(3-methoxypropyl)piperidin-4-yl]-1,2,4-oxadiazol-3-yl}-3-(propan-2-yl)-1H-indazole,

(02) 3-ethyl-1-{5-[1-(3-methoxypropyl)piperidin-4-yl]-1,2,4-oxadiazol-3-yl}-1H-indazole,

(03) 3-cyclopropyl-1-{5-[1-(3-methoxypropyl)piperidin-4-yl]-1,2,4-oxadiazol-3-yl}-1H-indazole,

(04) 3-ethyl-6-fluoro-1-{5-[1-(3-methoxypropyl)piperidin-4-yl]-1,2,4-oxadiazol-3-yl}-1H-indazole,

(05) 3-ethyl-7-fluoro-1-{5-[1-(3-methoxypropyl)piperidin-4-yl]-1,2,4-oxadiazol-3-yl}-1H-indazole,

(06) 1-{5-[1-(2-methylpropyl)piperidin-4-yl]-1,2,4-oxadiazol-3-yl}-3-(propan-2-yl)-1H-indazole,

(07) 1-{5-[1-(butan-2-yl)piperidin-4-yl]-1,2,4-oxadiazol-3-yl}-3-ethyl-1H-indazole,

(08) 1-{5-[1-(butan-2-yl)piperidin-4-yl]-1,2,4-oxadiazol-3-yl}-3-cyclopropyl-1H-indazole,

(09) 3-ethyl-1-{5-[1-(2-methylpropyl)piperidin-4-yl]-1,2,4-oxadiazol-3-yl}-1H-indazole,

(10) 1-{5-[1-(cyclopropylmethyl)piperidin-4-yl]-1,2,4-oxadiazol-3-yl}-3-ethyl-1H-indazole,

(11) 1-{5-[1-(butan-2-yl)piperidin-4-yl]-1,2,4-oxadiazol-3-yl}-3-cyclobutyl-1H-indazole,

(12) 3-cyclobutyl-1-{5-[1-(2-methylpropyl)piperidin-4-yl]-1,2,4-oxadiazol-3-yl}-1H-indazole,

(13) 3-(propan-2-yl)-1-[5-(1-propylpiperidin-4-yl)-1,2,4-oxadiazol-3-yl]-1H-indazole,

(14) 3-ethyl-6-fluoro-1-(5-{1-[2-(tetrahydrofuran-2-yl)ethyl]piperidin-4-yl}-1,2,4-oxadiazol-3-yl)-1H-indazole,

(15) 3-ethyl-1-{5-[1-(tetrahydrofuran-2-ylmethyl)piperidin-4-yl]-1,2,4-oxadiazol-3-yl}-1H-indazole,

(16) 3-ethyl-6-fluoro-1-{5-[1-(tetrahydro-2H-pyran-4-ylmethyl)piperidin-4-yl]-1,2,4-oxadiazol-3-yl}-1H-indazole,

(17) 3-ethyl-6-fluoro-1-(5-{1-[2-(tetrahydro-2H-pyran-4-yl)ethyl]piperidin-4-yl}-1,2,4-oxadiazol-3-yl)-1H-indazole,

(18) 3-ethyl-6-fluoro-1-{5-[1-(tetrahydrofuran-3-yl)piperidin-4-yl]-1,2,4-oxadiazol-3-yl}-1H-indazole,

(19) 3-ethyl-6-fluoro-1-{5-[1-(propan-2-yl)piperidin-4-yl]-1,2,4-oxadiazol-3-yl}-1H-indazole,

(20) methyl 4-({4-[3-(3-ethyl-6-fluoro-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}methyl)piperidine-1-carboxylate,

(21) methyl (2S)-2-({4-[3-(3-ethyl-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}methyl)pyrrolidine-1-carboxylate,

(22) 2-fluoroethyl (2S)-2-({4-[3-(3-ethyl-7-fluoro-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}methyl)pyrrolidine-1-carboxylate,

(23) 2-fluoroethyl (3S)-3-({4-[3-(3-ethyl-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}methyl)pyrrolidine-1-carboxylate,

(24) 1-[3-({4-[3-(3-ethyl-7-fluoro-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}methyl)azetidin-1-yl]-2-methoxyethanone,

(25) 1-{4-[3-(3-ethyl-6-fluoro-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]-1,4′-bipiperidin-1′-yl}ethanone,

(26) 1-{4-[3-(3-ethyl-7-fluoro-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]-1,4′-bipiperidin-1′-yl}ethanone,

(27) methyl 4-[3-(3-ethyl-6-fluoro-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]-1,4′-bipiperidine-1′-carboxylate,

(28) 1-(4-{3-[7-fluoro-3-(propan-2-yl)-1H-indazol-1-yl]-1,2,4-oxadiazol-5-yl}-1,4′-bipiperidin-1′-yl)ethanone,

(29) 1-(4-{3-[7-fluoro-3-(propan-2-yl)-1H-indazol-1-yl]-1,2,4-oxadiazol-5-yl}-1,4′-bipiperidin-1′-yl)-2-hydroxyethanone,

(30) methyl 4-{3-[3-(3-ethyl-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]azetidin-1-yl}piperidine-1-carboxylate,

(31) 3-{4-[3-(3-ethyl-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}propan-1-ol,

(32) cis-N-ethyl-3-[3-(3-ethyl-6-fluoro-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]cyclobutanamine,

(33) 1-[(3R)-3-({4-[3-(3-ethyl-7-fluoro-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}methyl)pyrrolidin-1-yl]ethanone,

(34) 1-[(3R)-3-({4-[3-(3-ethyl-7-fluoro-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}methyl)pyrrolidin-1-yl]-2-methoxyethanone,

(35) 1-[(3R)-3-({4-[3-(3-ethyl-7-fluoro-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}methyl)pyrrolidin-1-yl]-2-hydroxyethanone,

(36) 1-{4-[3-(3-ethyl-7-fluoro-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]-1,4′-bipiperidin-1′-yl}-2-hydroxyethanone,

(37) 1-{4-[3-(3-ethyl-7-fluoro-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]-1,4′-bipiperidin-1′-yl}-2-methoxyethanone,

(38) 4-[3-(3-ethyl-7-fluoro-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]-1′-(methylsulfonyl)-1,4′-bipiperidine,

(39) 1-(4-{3-[7-fluoro-3-(propan-2-yl)-1H-indazol-1-yl]-1,2,4-oxadiazol-5-yl}-1,4′-bipiperidin-1′-yl)-2-methoxyethanone,

(40) 1-[(3S)-3-({4-[3-(3-ethyl-7-fluoro-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}methyl)pyrrolidin-1-yl]ethanone,

(41) 1-[(3S)-3-({4-[3-(3-ethyl-7-fluoro-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}methyl)pyrrolidin-1-yl]-2-methoxyethanone,

(42) 3-ethyl-7-fluoro-1-[5-(1-{[(3S)-1-(methylsulfonyl)pyrrolidin-3-yl]methyl}piperidin-4-yl)-1,2,4-oxadiazol-3-yl]-1H-indazole,

(43) 3-ethyl-7-fluoro-1-[5-(1-{[(3R)-1-(methylsulfonyl)pyrrolidin-3-yl]methyl}piperidin-4-yl)-1,2,4-oxadiazol-3-yl]-1H-indazole,

(44) 1-[4-({4-[3-(3-ethyl-7-fluoro-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}methyl)piperidin-1-yl]-2-hydroxyethanone,

(45) 1-[3-({4-[3-(3-ethyl-7-fluoro-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}methyl)azetidin-1-yl]-2-hydroxyethanone,

(46) 1-{3-[(4-{3-[7-fluoro-3-(propan-2-yl)-1H-indazol-1-yl]-1,2,4-oxadiazol-5-yl}piperidin-1-yl)methyl]azetidin-1-yl}-2-methoxyethanone,

(47) 1-{3-[(4-{3-[7-fluoro-3-(propan-2-yl)-1H-indazol-1-yl]-1,2,4-oxadiazol-5-yl}piperidin-1-yl)methyl]azetidin-1-yl}ethanone,

(48) methyl 3-[(4-{3-[7-fluoro-3-(propan-2-yl)-1H-indazol-1-yl]-1,2,4-oxadiazol-5-yl}piperidin-1-yl)methyl]azetidine-1-carboxylate,

(49) 1-[3-({4-[3-(3-ethyl-7-fluoro-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}methyl)azetidin-1-yl]ethanone,

(50) 1-{(2R)-2-[(4-{3-[7-fluoro-3-(propan-2-yl)-1H-indazol-1-yl]-1,2,4-oxadiazol-5-yl}piperidin-1-yl)methyl]pyrrolidin-1-yl}-2-hydroxyethanone,

(51) 1-(4-{3-[7-fluoro-3-(propan-2-yl)-1H-indazol-1-yl]-1,2,4-oxadiazol-5-yl}-3′-methyl-1,4′-bipiperidin-1′-yl)-2-hydroxyethanone,

(52) 1-(3-{[(3R)-3-({3-[7-fluoro-3-(propan-2-yl)-1H-indazol-1-yl]-1,2,4-oxadiazol-5-yl}methyl)pyrrolidin-1-yl]methyl}azetidin-1-yl)ethanone,

(53) 1-(3-{[(3R)-3-({3-[7-fluoro-3-(propan-2-yl)-1H-indazol-1-yl]-1,2,4-oxadiazol-5-yl}methyl)pyrrolidin-1-yl]methyl}azetidin-1-yl)-2-hydroxyethanone,

(54) 1-[(3S)-3-{[(3R)-3-({3-[7-fluoro-3-(propan-2-yl)-1H-indazol-1-yl]-1,2,4-oxadiazol-5-yl}methyl)pyrrolidin-1-yl]methyl}pyrrolidin-1-yl]ethanone,

(55) 1-[(3S)-3-{[(3R)-3-({3-[7-fluoro-3-(propan-2-yl)-1H-indazol-1-yl]-1,2,4-oxadiazol-5-yl}methyl)pyrrolidin-1-yl]methyl}pyrrolidin-1-yl]-2-hydroxyethanone,

(56) 1-[(3R)-3-{[(3R)-3-({3-[7-fluoro-3-(propan-2-yl)-1H-indazol-1-yl]-1,2,4-oxadiazol-5-yl}methyl)pyrrolidin-1-yl]methyl}pyrrolidin-1-yl]-2-hydroxyethanone,

(57) 1-[(2S)-2-{[(3S)-3-({3-[7-fluoro-3-(propan-2-yl)-1H-indazol-1-yl]-1,2,4-oxadiazol-5-yl}methyl)pyrrolidin-1-yl]methyl}pyrrolidin-1-yl]-2-hydroxyethanone,

(58) 1-[(2R)-2-{[(3S)-3-({3-[7-fluoro-3-(propan-2-yl)-1H-indazol-1-yl]-1,2,4-oxadiazol-5-yl}methyl)pyrrolidin-1-yl]methyl}pyrrolidin-1-yl]-2-hydroxyethanone,

(59) 1-[(3S)-3-{[(3S)-3-({3-[7-fluoro-3-(propan-2-yl)-1H-indazol-1-yl]-1,2,4-oxadiazol-5-yl}methyl)pyrrolidin-1-yl]methyl}pyrrolidin-1-yl]-2-hydroxyethanone,

(60) 1-[(3R)-3-{[(3S)-3-({3-[7-fluoro-3-(propan-2-yl)-1H-indazol-1-yl]-1,2,4-oxadiazol-5-yl}methyl)pyrrolidin-1-yl]methyl}pyrrolidin-1-yl]-2-hydroxyethanone,

(61) 1-{4-[3-(3-ethyl-7-fluoro-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]-4′-methyl-1,4′-bipiperidin-1′-yl}-2-hydroxyethanon,

(62) 1-{4-[3-(3-ethyl-7-fluoro-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]-4′-methyl-1,4′-bipiperidin-1′-yl}-2-methoxyethanone,

(63) (2S)-1-{4-[3-(3-ethyl-7-fluoro-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]-4′-methyl-1,4′-bipiperidin-1′-yl}-2-hydroxypropan-1-one,

(64) 1-[(3S)-3-({4-[3-(3-ethyl-7-fluoro-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}methyl)pyrrolidin-1-yl]-2-hydroxyethanone,

(65) 1-[(2S)-2-({4-[3-(3-ethyl-7-fluoro-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}methyl)pyrrolidin-1-yl]-2-hydroxyethanone,

(66) 1-{4-[(3S)-3-{[3-(3-ethyl-7-fluoro-1H-indazol-1-yl)-1,2,4-oxadiazol-5-yl]methyl}pyrrolidin-1-yl]piperidin-1-yl}ethanone,

(67) 1-{4-[(3R)-3-({3-[7-fluoro-3-(propan-2-yl)-1H-indazol-1-yl]-1,2,4-oxadiazol-5-yl}methyl)pyrrolidin-1-yl]piperidin-1-yl}-2-methoxyethanone,

(68) 1-(3-{[(3R)-3-({3-[7-fluoro-3-(propan-2-yl)-1H-indazol-1-yl]-1,2,4-oxadiazol-5-yl}methyl)pyrrolidin-1-yl]methyl}azetidin-1-yl)-2-methoxyethanone,

(69) 1-[(3S)-3-{[(3R)-3-({3-[7-fluoro-3-(propan-2-yl)-1H-indazol-1-yl]-1,2,4-oxadiazol-5-yl}methyl)pyrrolidin-1-yl]methyl}pyrrolidin-1-yl]-2-methoxyethanone,

(70) 1-[(3R)-3-{[(3R)-3-({3-[7-fluoro-3-(propan-2-yl)-1H-indazol-1-yl]-1,2,4-oxadiazol-5-yl}methyl)pyrrolidin-1-yl]methyl}pyrrolidin-1-yl]-2-methoxyethanone,

(71) 1-{4-[(3S)-3-({3-[7-fluoro-3-(propan-2-yl)-1H-indazol-1-yl]-1,2,4-oxadiazol-5-yl}methyl)pyrrolidin-1-yl]piperidin-1-yl}-2-methoxyethanone,

(72) 1-(3-{[(3S)-3-({3-[7-fluoro-3-(propan-2-yl)-1H-indazol-1-yl]-1,2,4-oxadiazol-5-yl}methyl)pyrrolidin-1-yl]methyl}azetidin-1-yl)-2-methoxyethanone,

(73) 1-[(3S)-3-{[(3S)-3-({3-[7-fluoro-3-(propan-2-yl)-1H-indazol-1-yl]-1,2,4-oxadiazol-5-yl}methyl)pyrrolidin-1-yl]methyl}pyrrolidin-1-yl]-2-methoxyethanone, and

(74) 1-(4-{3-[7-fluoro-3-(propan-2-yl)-1H-indazol-1-yl]-1,2,4-oxadiazol-5-yl}-3′-methyl-1,4′-bipiperidin-1′-yl)ethanone.

16 . A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof.

17 . A serotonin-4 receptor agonist comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

18 . A medicament for treating Alzheimer-type dementia comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

19 . A method for treating a disease associated with serotonin-4 receptor comprising administering a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof to a patient in need thereof.

20 . A method for treating Alzheimer-type dementia comprising administering a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof to a patient in need thereof.